Biotech entity
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention pharma, the most common co-covered peer. They are better corroborated than the beat average, carrying 11 original sources each against 3.3 for the same window.
Last mentioned: Mar 17, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention pharma, the most common co-covered peer. They are better corroborated than the beat average, carrying 11 original sources each against 3.3 for the same window. Their average consequence score of 8 runs above the beat's 6.3 for that window. Cancer Drug Supply appears in 1 tracked Biotech story from March 17, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Cancer Drug Supply. Shared-story counts are live from our verified record — not editorial picks.
Rerouting Reports
Widespread reports confirm shipments are being rerouted via longer southern routes, adding significant transit time.
Oncology Inventory Warning
Major oncology associations warn of 'critical' inventory levels for chemotherapy agents at regional hospitals.
Force Majeure Notices
Global logistics providers issue Force Majeure notices for pharmaceutical shipments, initiating rerouting protocols.
Corridor Closures
Escalation of hostilities leads to the closure of primary maritime and air corridors for commercial cargo.
Geopolitical conflict has forced the pharmaceutical industry to abandon traditional shipping routes, leading to significant delays in the delivery of life-saving oncology treatments. Experts warn that the rerouting, which adds weeks to transit times, poses a direct threat to the global cancer drug supply chain and patient outcomes.
Cancer Drug Supply is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
